Study of the effect of different drug treatment strategies  in patients with hypertension

Oksana Rekovets; Yuriy Sirenko; Sergey  Progonov

doi:10.32345/USMYJ.1(144).2024.61-75

Oksana Rekovets State Institution “National Scientific Center “Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazhesko” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0002-3925-2948
Yuriy Sirenko State Institution “National Scientific Center “Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazhesko” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine https://orcid.org/0000-0002-4091-4910
Sergey Progonov State Institution “National Scientific Center “Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazhesko” of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

DOI: https://doi.org/10.32345/USMYJ.1(144).2024.61-75

Keywords: Amlodipine, Blood Pressure, Diltiazem, Drug Combinations, Hydrochlorothiazide, Hypertension, Metoprolol, Ramipril, Valsartan, lercanidipine

Abstract

fixed combinations of antihypertensive medications can improve blood pressure (BP) control, reduce complications and increase life expectancy. The objective of our study was to analyze the efficiency of fixed, free and not traditional combinations of antihypertensive medications in the management of patients with arterial hypertension. 396 patients with hypertension with various degrees of its severity were examined. The inclusion criteria were the age of patients older than 18 years and the level of office BP greater than 140/90 mm Hg. Patients were in three observational groups: traditional free combinations, traditional fixed combinations, and not traditional free combinations. 91 patients received an unfixed combination of ramipril and hydrochlorothiazide. 132 patients received an unfixed combination of metoprolol-retard and hydrochlorothiazide. 50 patients were assigned to group with studying the effect of fixed traditional double and triple combinations of antihypertensive medications. The last 123 patients with hypertension comprised the group of studying the effect of dihydropyridine and non-dihydropyridine calcium blockers on the degree of BP reduction and the development of adverse events. The use of metoprolol-retard 100-300 mg per day in patients with mild to moderate hypertension provided a significant decrease in office BP: SBP/ DBP – 32/18 mm Hg, heart rate (HR) - 18 bpm, ABPM: 24SBP/DBP – 21/13 mm Hg and HR - 7 bpm. Achievement of the target BP 93.6% office BP and in 84,9% - ABPM. The use of ramipril 10 mg in combination with hydrochlorothiazide 25 mg in patients with mild and moderate arterial hypertension provided a reliable reduction of both office SBP/DBP - 36,6/17,2 mm Hg and ABPM 24SBP/DBP - 18,9/7,0 mm Hg. The prescribed monotherapy of lercanidipine 20 mg or a low-dose combination of lercanidipine 10 mg and diltiazem 120 mg were most effectively tolerated treatment. Combined treatment based on lercanidipine and diltiazem had similar efficiency as treatment based on monotherapy with lercanidipine, according to both office and ABPM measurements. Patients taking fixed triple combination of valsartan/hydrochlorothiazide/amlodipine had decrease 24SBP/DBP - 23.8/20.7 mmHg (p<0,05). This improvement of BP on this combination was also observed during the day and night period - 27.4/22.6 mmHg and 20.5/18.2 mm Hg, respectively (р<0.05). Achieved the target blood pressure during ABPM was 77.3% in the group of fixed double therapy valsartan/amlodipine and 95.2% in the triple combination valsartan/amlodipine/hydrochlorothiazide. The triple fixed combination of valsartan/ hydrochlorothiazide /amlodipine was the most effective in lowering blood pressure according to data of office measurement and 24 hours monitoring. It contributed to the achievement of target blood pressure levels at office measurement - 95.7% and at ABPM - 95.2%.

References

Allemann, Y., Fraile, B., Lambert, M., Barbier, M., Ferber, P., & Izzo, J. L., Jr (2008). Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. Journal of clinical hypertension (Greenwich, Conn.), 10(3), 185–194. https://doi.org/10.1111/j.1751-7176.2008.07516.x

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288(23), 2981–2997. https://doi.org/10.1001/jama.288.23.2981

Assaad-Khalil, S. H., & Nashaat, N. (2016). Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study. Drugs - real world outcomes, 3(3), 307–315. https://doi.org/10.1007/s40801-016-0082-5

Baser, O., Andrews, L. M., Wang, L., & Xie, L. (2011). Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. Journal of medical economics, 14(5), 576–583. https://doi.org/10.3111/13696998.2011.596873

Boggia, J., Li, Y., Thijs, L., Hansen, T. W., Kikuya, M., Björklund-Bodegård, K., Richart, T., Ohkubo, T., Kuznetsova, T., Torp-Pedersen, C., Lind, L., Ibsen, H., Imai, Y., Wang, J., Sandoya, E., O'Brien, E., Staessen, J. A., & International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) investigators (2007). Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet (London, England), 370(9594), 1219–1229. https://doi.org/10.1016/S0140-6736(07)61538-4

Boutouyrie, P., Achouba, A., Trunet, P., Laurent, S., & EXPLOR Trialist Group (2010). Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension (Dallas, Tex. : 1979), 55(6), 1314–1322. https://doi.org/10.1161/HYPERTENSIONAHA.109.148999

Calhoun, D. A., Crikelair, N. A., Yen, J., & Glazer, R. D. (2009). Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. Advances in therapy, 26(11), 1012–1023. https://doi.org/10.1007/s12325-009-0077-7

Calhoun, D. A., Lacourcière, Y., Crikelair, N., Jia, Y., & Glazer, R. D. (2013). Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Current medical research and opinion, 29(8), 901–910. https://doi.org/10.1185/03007995.2013.803057

Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P. O. (1993). Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) analyses performed up to 1992. Clinical and experimental hypertension (New York, N.Y. : 1993), 15(6), 925–939. https://doi.org/10.3109/10641969309037082

Dahlöf, B., Lindholm, L. H., Hansson, L., Scherstén, B., Ekbom, T., & Wester, P. O. (1991). Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet (London, England), 338(8778), 1281–1285. https://doi.org/10.1016/0140-6736(91)92589-t

Destro, M., Luckow, A., Samson, M., Kandra, A., & Brunel, P. (2008). Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. Journal of the American Society of Hypertension : JASH, 2(4), 294–302. https://doi.org/10.1016/j.jash.2008.01.004

DREAM Trial Investigators, Bosch, J., Yusuf, S., Gerstein, H. C., Pogue, J., Sheridan, P., Dagenais, G., Diaz, R., Avezum, A., Lanas, F., Probstfield, J., Fodor, G., & Holman, R. R. (2006). Effect of ramipril on the incidence of diabetes. The New England journal of medicine, 355(15), 1551–1562. https://doi.org/10.1056/NEJMoa065061

Duprez, D. A., Weintraub, H. S., Cushman, W. C., Purkayastha, D., Zappe, D., Samuel, R., & Izzo, J. L., Jr (2011). Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy. Blood pressure monitoring, 16(4), 186–196. https://doi.org/10.1097/MBP.0b013e32834944e9

Flack, J. M., Calhoun, D. A., Satlin, L., Barbier, M., Hilkert, R., & Brunel, P. (2009). Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. Journal of human hypertension, 23(7), 479–489. https://doi.org/10.1038/jhh.2008.153

Genth-Zotz, S., Zotz, R. J., Sigmund, M., Hanrath, P., Hartmann, D., Böhm, M., Waagstein, F., Treese, N., Meyer, J., & Darius, H. (2000). MIC trial: metoprolol in patients with mild to moderate heart failure: effects on ventricular function and cardiopulmonary exercise testing. European journal of heart failure, 2(2), 175–181. https://doi.org/10.1016/s1388-9842(00)00078-7

Hansson L. (2000). Results of the STOP-Hypertension-2 trial. Blood pressure. Supplement, 2, 17–20.

Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., Karlberg, B. E., Wester, P. O., & Björck, J. E. (1999). Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet (London, England), 353(9153), 611–616. https://doi.org/10.1016/s0140-6736(98)05012-0

Johannesson, M., Dahlöf, B., Lindholm, L. H., Ekbom, T., Hansson, L., Odén, A., Scherstén, B., Wester, P. O., & Jönsson, B. (1993). The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Journal of internal medicine, 234(3), 317–323. https://doi.org/10.1111/j.1365-2796.1993.tb00749.x

Kafrawy, Nabil & Rashwan, Magdy & Lion, Khaled & Khedr, Kawkab & Nashaat, Nashwa. (2014). Effectiveness and tolerability of fixed dose combination of amlodipine/valsartan in treatment of hypertension in the real-life setting among Egyptian patients. The Egyptian Heart Journal, 66(1):30–35. https://doi.org/10.1016/j.ehj.2013.12.033

Kaplan N. M. (1996). The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clinical therapeutics, 18(4), 658–670. https://doi.org/10.1016/s0149-2918(96)80216-5

Kario, K., Tomitani, N., Kanegae, H., Ishii, H., Uchiyama, K., Yamagiwa, K., Shiraiwa, T., Katsuya, T., Yoshida, T., Kanda, K., Hasegawa, S., & Hoshide, S. (2017). Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The NOCTURNE Study. Circulation journal : official journal of the Japanese Circulation Society, 81(7), 948–957. https://doi.org/10.1253/circj.CJ-17-0109

Khan, W., Moin, N., Iktidar, S., Sakrani, J., Abid, R., Afzal, J., Maheshwary, N., Kumar, K., Siddiqi, A., & Qadir, M. (2014). Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. Therapeutic advances in cardiovascular disease, 8(2), 45–55. https://doi.org/10.1177/1753944714525496

Kjekshus J. K. (1988). According to MIAMI and ISIS-I trials, can a general recommendation be given for beta blockers in acute myocardial infarction? Cardiovascular drugs and therapy, 2(1), 113–119. https://doi.org/10.1007/BF00054261

LaPalio, L., Schork, A., Glasser, S., & Tifft, C. (1992). Safety and efficacy of metoprolol in the treatment of hypertension in the elderly. Journal of the American Geriatrics Society, 40(4), 354–358. https://doi.org/10.1111/j.1532-5415.1992.tb02134.x

Lash, J. P., Wang, X., Greene, T., Gadegbeku, C. A., Hall, Y., Jones, K., Kusek, J. W., Sika, M., Unruh, M., & African American Study of Kidney Disease and Hypertension Trial Study Group (2006). Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. American journal of kidney diseases : the official journal of the National Kidney Foundation, 47(6), 956–964. https://doi.org/10.1053/j.ajkd.2006.02.175

Lins, R., Aerts, A., Coen, N., Hermans, C., MacDonald, K., Brié, H., Lee, C., Shen, Y. M., Vancayzeele, S., Mecum, N., & Abraham, I. (2011). Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study). The Annals of pharmacotherapy, 45(6), 727–739. https://doi.org/10.1345/aph.1P663

Luomanmäki, K., Inkovaara, J., Hartikainen, M., Helin, M., Viikari, J., Kataja, M., Ekman, K., & Harjula, K. (1992). Efficacy and tolerability of isradipine and metoprolol in treatment of hypertension: the Finnish Isradipine Study in Hypertension (FISH). Journal of cardiovascular pharmacology, 20(2), 296–303. https://doi.org/10.1097/00005344-199208000-00016

Mallat, S. G., Itani, H. S., & Tanios, B. Y. (2013). Current perspectives on combination therapy in the management of hypertension. Integrated blood pressure control, 6, 69–78. https://doi.org/10.2147/IBPC.S33985

Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., Galderisi, M., Grobbee, D. E., Jaarsma, T., Kirchhof, P., Kjeldsen, S. E., Laurent, S., Manolis, A. J., Nilsson, P. M., Ruilope, L. M., Schmieder, R. E., … Task Force Members (2013). 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of hypertension, 31(7), 1281–1357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc

Marre, M., Lievre, M., Chatellier, G., Mann, J. F., Passa, P., Ménard, J., & DIABHYCAR Study Investigators (2004). Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ (Clinical research ed.), 328(7438), 495. https://doi.org/10.1136/bmj.37970.629537.0D

Matsui, Y., Eguchi, K., O'Rourke, M. F., Ishikawa, J., Miyashita, H., Shimada, K., & Kario, K. (2009). Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension (Dallas, Tex. : 1979), 54(4), 716–723. https://doi.org/10.1161/HYPERTENSIONAHA.109.131466

Mayer-Hamblett, N., Ratjen, F., Russell, R., Donaldson, S. H., Riekert, K. A., Sawicki, G. S., Odem-Davis, K., Young, J. K., Rosenbluth, D., Taylor-Cousar, J. L., Goss, C. H., Retsch-Bogart, G., Clancy, J. P., Genatossio, A., O'Sullivan, B. P., Berlinski, A., Millard, S. L., Omlor, G., Wyatt, C. A., Moffett, K., … SIMPLIFY Study Group (2023). Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. The Lancet. Respiratory medicine, 11(4), 329–340. https://doi.org/10.1016/S2213-2600(22)00434-9

Ogihara, T., Saruta, T., Rakugi, H., Matsuoka, H., Shimamoto, K., Shimada, K., Imai, Y., Kikuchi, K., Ito, S., Eto, T., Kimura, G., Imaizumi, T., Takishita, S., Ueshima, H., & Valsartan in Elderly Isolated Systolic Hypertension Study Group (2010). Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (Dallas, Tex. : 1979), 56(2), 196–202. https://doi.org/10.1161/HYPERTENSIONAHA.109.146035

Oparil, S., Giles, T., Ofili, E. O., Pitt, B., Seifu, Y., Hilkert, R., Samuel, R., & Sowers, J. R. (2011). Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. Journal of hypertension, 29(1), 161–170. https://doi.org/10.1097/HJH.0b013e32834000a7

Philipp, T., Smith, T. R., Glazer, R., Wernsing, M., Yen, J., Jin, J., Schneider, H., & Pospiech, R. (2007). Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clinical therapeutics, 29(4), 563–580. https://doi.org/10.1016/j.clinthera.2007.03.018

Pogue, V., Rahman, M., Lipkowitz, M., Toto, R., Miller, E., Faulkner, M., Rostand, S., Hiremath, L., Sika, M., Kendrick, C., Hu, B., Greene, T., Appel, L., Phillips, R. A., & African American Study of Kidney Disease and Hypertension Collaborative Research Group (2009). Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension (Dallas, Tex. : 1979), 53(1), 20–27. https://doi.org/10.1161/HYPERTENSIONAHA.108.115154

Rekovets O., Sirenko Yu., Torbas O., Kushnir S., Primak G. The use of fixed double and triple combinations in achieving the target level of blood pressure during daily monitoring in patients with arterial hypertension. Bukovynskyi Medychnyi Visnyk. 2020, № 2 (94), с. 102-112. https://doi.org/10.24061/2413-0737. XXIV.2.94.2020.50

Sawada, T., Yamada, H., Dahlöf, B., Matsubara, H., & KYOTO HEART Study Group (2009). Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. European heart journal, 30(20), 2461–2469. https://doi.org/10.1093/eurheartj/ehp363 (Retraction published Eur Heart J. 2013 Apr;34(14):1023)

Schrader, J., Lüders, S., Kulschewski, A., Hammersen, F., Züchner, C., Venneklaas, U., Schrandt, G., Schnieders, M., Rangoonwala, B., Berger, J., Dominiak, P., Zidek, W., & MARPLE Study Group (2006). Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. Journal of hypertension, 24(3), 541–548. https://doi.org/10.1097/01.hjh.0000209991.48928.c4

Sirenko Yu., Rekovets O., Andriyevskaya S., Babak O., Govorova O., Rudyk Yu. Antihypertensive efficacy of ramipril in patients with mild and moderate arterial hypertension (results of the multicenter study RASH - Ramipril Study in patient with arterial Hypertension). Ukrayinsky cardiologichnyi journal. – 2007. - №1. – С. 41-47

Sirenko Yu., Rekovets O., Dobrokhod A. Evaluation of the effect of mono- and combined antihypertensive therapy with dihydropyridine and non-dihydropyridine calcium antagonists on office blood pressure and blood pressure during daily monitoring in patients with mild and moderate arterial hypertension "Arterialna hypertensia" 1 (45) 2016, С. 45 – 66.

Sirenko Yu., Rekovets O. The influence of metoprolol-retard on the morning rise in blood pressure in patients with mild and moderate arterial hypertension according to 24-hour blood pressure monitoring. Ukrayinsky cardiologichnyi journal. - 2006. - № 3. - С. 73-77

Sison, J., Assaad-Khalil, S. H., Najem, R., Kitchlew, A. R., Cho, B., Ueng, K. C., Shete, A., & Knap, D. (2014). Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. Current medical research and opinion, 30(10), 1937–1945. https://doi.org/10.1185/03007995.2014.942415

Sison, J., Vega, R. M. R., Dayi, H., Bader, G., & Brunel, P. (2018). Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized controlled versus observational studies. Current medical research and opinion, 34(3), 501–515. https://doi.org/10.1080/03007995.2017.1412682

Sleight P. (2000). The HOPE Study (Heart Outcomes Prevention Evaluation). Journal of the renin-angiotensin-aldosterone system : JRAAS, 1(1), 18–20. https://doi.org/10.3317/jraas.2000.002

Waeber, B., & Ruilope, L. M. (2009). Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vascular health and risk management, 5(1), 165–174. https://doi.org/10.2147/vhrm.s3134

Weycker, D., Keskinaslan, A., Levy, D. G., Edelsberg, J., Kartashov, A., & Oster, G. (2008). Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan. Blood pressure. Supplement, 2, 5–12. https://doi.org/10.1080/08038020802316536

White W. Blood pressure monitoring in cardiovascular medicine and therapeutics. – New Jersey: Humana Press, 2001. – 308 p.